A Study to Evaluate MesilatE for Treating Hospitalized Patients with COVID-19 (Enrolling by Invitation Only)


About this study

The primary purpose of this study is to determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Laboratory confirmed SARS-CoV-2 infection.
  • Admitted to hospital for management of SARS-CoV-2.
  • Age ≥ 18 years old.
  • Subject or legal representative able to give informed consent.
  • Ability to take all study drugs.
  • Willingness to provide mandatory specimens for correlative research and banking.

Exclusion Criteria:

  • Individuals under 18 years of age.
  • Women who are pregnant or breastfeeding.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Sadia Shah, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Alan Bryce, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer